[Evolution of HIV and HCV coinfected children receiving long-term lopinavir/ritonavir-based antiretroviral therapy]

Enferm Infecc Microbiol Clin. 2008 Aug-Sep;26(7):426-9. doi: 10.1157/13125640.
[Article in Spanish]

Abstract

Introduction: There are few studies investigating the effect of HCV coinfection on HIV-related disease among children.

Methods: We studied 5 HIV/HCV coinfected children receiving an LPV/r-containing HAART regimen. Their evolution was compared with a control group of 72 HIV-infected children.

Results: All 5 HIV/HCV-coinfected children achieved sustained immune recovery during the study. Moreover, they showed better viral suppression than the control group. None of the 5 HIV/HCV-coinfected children experienced any adverse effects with the use of LPV/r.

Conclusion: HIV/HCV coinfection does not reduce the benefits obtained from HAART.

Publication types

  • English Abstract
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active*
  • Child
  • Child, Preschool
  • Disease Progression
  • Female
  • Follow-Up Studies
  • HIV Infections / drug therapy
  • HIV Infections / epidemiology*
  • HIV Protease Inhibitors / administration & dosage
  • HIV Protease Inhibitors / therapeutic use
  • Hepatitis C / drug therapy
  • Hepatitis C / epidemiology*
  • Humans
  • Infant
  • Lopinavir
  • Male
  • Pyrimidinones / administration & dosage
  • Pyrimidinones / therapeutic use*
  • Retrospective Studies
  • Ritonavir / administration & dosage
  • Ritonavir / therapeutic use*

Substances

  • Anti-HIV Agents
  • HIV Protease Inhibitors
  • Pyrimidinones
  • Lopinavir
  • Ritonavir